Sera Prognostics Q2 2026 Earnings: Commercial Progress Has Yet to Produce Material Revenue

Sera Prognostics (Nasdaq: SERA) reported Q2 2026 revenue of $30,000, up from $17,000 a year earlier, while basic and diluted net loss per share widened to $0.18 from $0.16. Net loss increased to $9.1 million as operating expenses rose, even as the company expanded payer engagement and access for its PreTRM test. Cash and available-for-sale securities totaled approximately $80.3 million at quarter-end.

Core Financial Results

Revenue grew by approximately 76% year over year, but the $13,000 absolute increase underscores that Sera remains in the early stages of commercialization. Total operating expenses of $10.0 million remained far above quarterly revenue.

The wider net loss reflected both higher spending and lower other income. Operating expenses increased by $697,000, while other income, net declined by $409,000 to $867,000.

R&D expenses included restructuring-related costs, and the company said it expects this category to decline in future periods. The increase in selling, marketing and administrative spending reflected commercial programs, marketing investment and strategic hiring.

Business and Commercial Progress

Sera said testing volume has increased steadily month to month since publication of the PRIME study, although it did not disclose test counts or the revenue contribution from that increase. The company also exceeded its 2026 payer engagement objective, with active discussions covering more than 20 payer opportunities across more than 20 states.

In August 2026, Sera launched its fourth partnership program through a state-based initiative with a national payer. The company is now emphasizing implementation, reimbursement readiness and adoption in priority markets.

Illinois also enacted legislation in June requiring Medicaid coverage and reimbursement for prescribed proteomic blood tests used to identify spontaneous preterm birth risk. A subsequent provider notice confirmed that the coverage applies to all Medicaid pregnancies in the state, representing approximately 50,000 annual births. The policy expands potential access, but Sera did not quantify its expected effect on testing volume or revenue.

Clinical evidence remains central to the commercial strategy. A published PRIME subgroup analysis found that PreTRM test-guided care reduced NICU admissions by 22% among first-time mothers and severe composite neonatal morbidity by 30%. The analysis reported that 28 first-time pregnancies needed to be screened and treated to prevent one NICU admission.

For Europe, Sera completed additional assay performance testing and expects CE-marking pre-application activities to begin in Q3 2026, with submission of the package scheduled to conclude in Q4 2026.

Profitability, Liquidity and the Balance Sheet

Sera ended June with $4.4 million in cash and cash equivalents, $42.0 million in current marketable securities and $33.8 million in long-term marketable securities. Together, these totaled approximately $80.3 million, compared with approximately $95.8 million at the end of 2025—a decline of about $15.5 million over six months.

That balance-sheet reduction should not be treated as a direct measure of free cash flow because the release did not provide a cash flow statement. Management believes current resources can fund operations through significant adoption and commercialization milestones through 2029.

Deferred revenue was largely unchanged at $20.3 million, compared with $20.3 million at the end of 2025. Total liabilities increased to $27.4 million from $26.5 million.

Commercial Access Is Advancing Faster Than Reported Revenue

The central issue in Q2 was the gap between commercial groundwork and recognized revenue. Payer discussions, partnership programs, Illinois Medicaid coverage and additional clinical evidence could support broader adoption, but quarterly revenue remained only $30,000 while commercial and administrative spending increased.

The next stage of the story therefore depends on whether expanded access produces reimbursed testing volume. Payer engagement and clinical publications are leading indicators, but they have not yet translated into revenue at a scale that materially offsets the company’s operating cost base.

Recent Insider Transactions

The available insider data show three direct stock sales on June 11, 2026, all executed at $2.01 per share. The source provided transaction values but did not disclose the number of shares sold, so no conclusions about insider sentiment can be drawn from these records alone.

The supplied data also listed seven zero-price director stock awards dated July 10, 2026, but did not provide the number of shares granted.

Risks Investors Need to Watch

• Limited commercial scale: Revenue remains minimal relative to the $10.0 million quarterly operating expense base, making sustained losses likely unless reimbursed testing volume increases materially.
• Coverage-to-revenue conversion: Payer discussions and Illinois Medicaid coverage expand potential access, but the company has not quantified how these developments will affect paid tests or revenue.
• Liquidity consumption: Cash and securities declined by approximately $15.5 million during the first six months of 2026. The runway through 2029 is management’s current estimate and depends on future spending and commercialization progress.
• Product and customer concentration: The PreTRM test has generated substantially all company revenue to date, and Sera disclosed dependence on a concentrated number of material customers.
• Regulatory and market acceptance: European expansion depends on completing the CE-marking process, while broader performance depends on physician adoption and third-party reimbursement.

Summary

Sera Prognostics made progress on payer engagement, Medicaid access and clinical validation in Q2 2026, but those developments have not yet produced material revenue. Higher commercial spending and lower other income widened the net loss, while the $80.3 million liquidity balance provides time to pursue adoption. The key measure ahead is whether expanded coverage and partnerships convert into reimbursed test volume without causing spending to rise faster than commercialization.